You are here

  • Home
  • Archive
  • Volume 10, Issue 4
  • Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial

 

Online download statistics by month:

Online download statistics by month: April 2022 to July 2025

AbstractFullPdf
Apr 2022925943484
May 2022708717362
Jun 2022707716212
Jul 2022452455167
Aug 2022406420161
Sep 2022423430164
Oct 2022385390157
Nov 2022333333174
Dec 202218818998
Jan 202318418490
Feb 2023215215133
Mar 2023220220135
Apr 2023205209123
May 2023189191121
Jun 202314214293
Jul 2023180182132
Aug 2023173174108
Sep 202313813895
Oct 2023145145108
Nov 2023155155107
Dec 2023238238171
Jan 2024171175146
Feb 2024175175133
Mar 2024235239217
Apr 2024201205163
May 2024189190148
Jun 2024183184122
Jul 2024208209276
Aug 2024202202101
Sep 2024170172334
Oct 2024168169129
Nov 2024219222166
Dec 2024278290203
Jan 2025184190121
Feb 2025284287200
Mar 2025296303227
Apr 2025382383190
May 2025231235161
Jun 202514014495
Jul 2025110
Total10628107616527